Key result
Beta-adrenergic blocking drugs may reduce elevated blood pressure by normalizing increased heart rate and stroke volume.
Discusses the physiological rationale for using beta-adrenergic blocking drugs to treat hypertension by reducing heart rate and stroke volume.
Establishes distinct α/β receptor roles in vascular and cardiac responses; leaves open targeted therapeutic applications pending validation.
THE DESIGNATION of α- and β-adrenergic receptors in vascular smooth muscle¹has proved useful in describing adrenergic function. Alpha-receptors, when stimulated, produce peripheral vasoconstriction which can be blocked by such pharmacological agents as phenoxybenzamine or phentolamine. Stimulation of β-receptors produces increased inotropic and chronotropic myocardial activity, as well as peripheral vasodilation; these responses can be blocked by dichloroisoproterenol, pronethalol, or propranolol. Use of β-adrenergic blocking drugs in treatment of hypertension may at first seem paradoxical, since inhibition of a neural mechanism serving vasodilation is contrary to current physiological thinking. However, vascular resistance is not the sole determinant of pressure; blood flow is the other dependent variable. If, therefore, elevated blood pressure could be ascribed to an increase in flow or its determining variables, heart rate and stroke volume, normalization of these factors may provide a specific therapeutic measure in its reduction. Increased β-activity can, therefore, produce hypertension if blood
No takes yet. Share an insight, caveat, or question.
E. D. Frohlich (1966) conducted a review in hypertension. beta-adrenergic blocking drugs was evaluated. Beta-adrenergic blocking drugs may reduce elevated blood pressure by normalizing increased heart rate and stroke volume.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: